Biogen shares soar on landmark Alzheimer's data, lift rivals

RTÉ

Center

High Factuality

Government: Government of Ireland

Biogen and Eisai stocks soar on Alzheimer's success

Shares in Biogen and Eisai soared today reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly.

IBTimes

Center

Mixed Factuality

Media Conglomerate: IBT Media

Biogen, Eisai Stocks Soar On Landmark Alzheimer's Data, Lifting Rivals

Shares in Biogen and Eisai soared on Wednesday reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly.

Benzinga

Center

High Factuality

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen (NASDAQ:BIIB)

El Pais

Lean Left

High Factuality

Media Conglomerate: PRISA

Biogen and Eisai skyrocket on the stock market after proclaiming successful trials of a drug against Alzheimer's

The shares of the US pharmaceutical company Biogen and those of the Japanese company Eisai skyrocketed this Wednesday on the stock market after both companies announced on Tuesday night the success in clinical trials of a compound to stop cognitive impairment caused by Alzheimer's, the most widespread disease that causes dementia and that affects about 50 million people worldwide (about 800,000 in Spain) .Continue reading

Seeking Alpha

Lean Right

High Factuality

Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial

travellinglight/iStock via Getty Images Biogen (NASDAQ:BIIB) and Japanese drugmaker Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced their experimental Alzheimer’s medication lecanemab met the main goal in a large-stage trial, sparking pre-market gains Wednesday… This News Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial appeared first on STL.News.